中文摘要：

瞄准：在试验性的 hepatorenal 症候群(HRS ) 的致病调查 heme oxygenase-1 (HO-1 ) 的角色。方法：老鼠被划分成肝肝脏硬化症的组，锌 protoporphyrin IX (ZnPP ) 处理组，钴 protoporphyrin (CoPP ) 处理组和假冒的组。胆汁的肝硬化被胆汁管结扎在开始的三个组建立。分别地，在 ZnPP 和 CoPP 处理组的老鼠收到了 ZnPP 和 CoPP 的 intraperitoneal 注射在样品收集前的 24 h。在肾的 HO-1 mRNA 的表示被反向抄写的聚合酶链反应检测，当蛋白质表示被 immunohistochemical 分析决定时。Hematoxylin 并且曙红染色被执行观察肝肝硬化和肾的结构。肾的动脉血流动，吝啬的动脉的压力和门静脉迫使，尿体积，浆液和尿钠集中，和 creatinine 清理评估的 24 h 总数(Ccr ) 也被测量。结果：在肾的 HO-1 mRNA 和蛋白质表示层次， 24 h 总数尿体积，肾的动脉血流动，浆液和尿钠集中和 Ccr 比在假冒的组在肝脏硬化症的组是更低的(P < 0.05 ) 。然而，他们在 CoPP 处理组更高比在肝脏硬化症的组并且显著地在 ZnPP 处理组是显著地更低的比在肝脏硬化症的组(P < 0.05 ) 。结论：在肾的低 HO-1 表示水平是为试验性的 HRS 的一个重要因素。

英文摘要：

AIM： To investigate the role of heme oxygenase-1 （HO-1） in pathogenesis of experimental hepatorenal syndrome （HRS）. METHODS： Rats were divided into liver cirrhotic group, zinc protoporphyrin IX （ZnPP） treatment group, cobalt protoporphyrin （CoPP） treatment group and sham group. Biliary cirrhosis was established by bile duct ligation in the first three groups. Rats in the ZnPP and CoPP treatment groups received intraperitoneal injection of ZnPP and CoPP, respectively, 24 h before sample collection. Expression of HO-1 mRNA in kidney was detected by reverse-transcription polymerase chain reaction, while protein expression was determined by immunohis-tochemical analysis. Hematoxylin and eosin staining was performed to observe liver cirrhosis and renal structure. Renal artery blood flow, mean arterial pressure and portal vein pressure, 24 h total urinary volume, serum and urine sodium concentrations, and creatinine clearance rate （Ccr） were also measured.RESULTS： The HO-1 mRNA and protein expression levels in kidney, 24 h total urinary volume, renal artery blood flow, serum and urine sodium concentration and Ccr were lower in cirrhotic group than in sham group （P 0.05）. However, they were significantly lower in ZnPP treatment group than in cirrhotic group and significantly higher in CoPP treatment group than in cirrhotic group （P 0.05）. CONCLUSION： Low HO-1 expression level in kidney is an important factor for experimental HRS.